项目名称: 基于PI3K/AKT信号通路研究新风胶囊抑制AA大鼠血小板微粒释放的机制
项目编号: No.81473672
项目类型: 面上项目
立项/批准年度: 2015
项目学科: 医药、卫生
项目作者: 黄传兵
作者单位: 安徽中医药大学
项目金额: 74万元
中文摘要: 类风湿关节炎(RA)基本病理变化为滑膜炎和血管翳,血小板活化后释放血小板微粒是RA病理进展的重要启动因素之一。PI3K/AKT通路介导的血小板释放炎性介质、细胞因子,直接参与RA发病过程。因此,调整PI3K/AKT通路的平衡可成为控制免疫炎症、血管新生,抑制RA血管翳及骨质破坏的一个治疗靶点。本课题组根据中医脾虚致瘀病机,创制治痹效方新风胶囊(XFC),结合前期研究基础,采用体内外结合的研究方法,研究XFC通过调控PI3K/AKT通路活性,抑制血小板活化,减少血小板微粒释放,改善RA病情的假说。为验证这一假说,系统研究佐剂关节炎(AA)大鼠血小板超微结构、血小板活化标志物-血小板微粒、PI3K/AKT通路的变化特征及健脾化湿通络中药XFC对其影响,阐明XFC抑制AA大鼠血小板微粒释放机制及PI3K/AKT通路重要分子的影响,揭示PI3K/AKT通路在AA大鼠血小板微粒释放的作用。
中文关键词: 类风湿关节炎;新风胶囊;PI3K/AKT;信号通路
英文摘要: Rheumatoid arthritis(RA) is a basic pathological changes of synovitis and pannus formation, platelet activation after the release of platelet microparticles is an important factor in starting the pathological progression of RA .P13K/AKT signaling pathway and mediates platelet microparticles release of inflammatory mediators, cytokines, directly involved in the pathogenesis of RA. Therefore, adjusting the P13K/AKT signaling pathway controls the balance is expected to become immune inflammation, inhibit angiogenesis,thereby inhibiting a therapeutic target in RA pannus formation and bone destruction, We according to Chinese medicine, Spleen cause stasis. Pathogenesis, create governance paralysis effect side Xinfeng Capsule(XFC), combined with previous studies based on research methods in vivo Foreign Secretary, research XFC by regulating P13K/AKT signaling pathway activity,inhibition of platelet activation,reduce the release of platelet microparticles improve the hypothesis of RA . To test this hypothesis, the systematic study of rat platelet ultrastructure in adjuvant arthritis (AA), platelet activation markers-platelet microparticles, P13K/AKT pathway variations and Jianpihuashitongluo of Chinese medicine XFC its impact clarify Xinfeng Capsule AA inhibition of rat platelet microparticles release mechanism and PI3K/AKT pathways important molecules, revealing PI3K/AKT pathways in rat platelet microparticles AA release effect.
英文关键词: Rheumatoid Arthritis;Xinfeng Capsule;PI3K/AKT pathway